Tenderwize
Back to tender search

Open house drug discount agreements

AOK NordWest - Die Gesundheitskasse·Dortmund, Germany·Deadline May 14, 2027 · 271 days left·Open·Supplies
Original notice title

Germany – Pharmaceutical products – Arzneimittel-Rabattverträge gem. § 130a (8c) SGB V ab 01.08.2025 zu diversen Wirkstoffen im Rahmen eines Open-House-Verfahrens

58/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Why this score?

Opportunity

58 / 100

Complexity

62 / 100

Risk factors

The metadata marks electronic submission as not allowed, but the notice text requires electronic submission by email be...

The structured deadline fallback date (2027-05-14) differs from the notice text stating the latest contract conclusion...

Deep Portfolio Analysis

Deep Company Fit Analysis

Uses:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Overview

Moderate opportunity

Key Facts

  • Supplies contract
  • 3 lots
  • Duration until Jul 2027
  • Non-exclusive rebate agreements under Section 130a(8c) SGB V for oncology parenteral preparations made from finished medicinal products.
  • Active substances listed: bevacizumab (L01FG01), eribulin (L01XX41), rituximab (L01FA01), trastuzumab (L01FD01).
Show full summary

Open-house pharmaceutical rebate agreement notice for three German regional lots (North Rhine-Westphalia, Hamburg, Schleswig-Holstein) covering oncology parenteral preparations made from finished medicinal products. The arrangement is non-exclusive, identical for all interested eligible pharmaceutical companies, with no award competition and no negotiated terms. Contract start is earliest 2025-08-01, duration up to 24 months, and the latest contract conclusion date is 2027-05-21. Submission is by email plus signed originals; electronic submission is otherwise marked not allowed in the notice metadata, so the submission mechanics should be checked carefully.

Risks

The metadata marks electronic submission as not allowed, but the notice text requires electronic submission by email be...

The structured deadline fallback date (2027-05-14) differs from the notice text stating the latest contract conclusion...

Analysis may be incomplete

Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.

Key Requirements

Technical

  • Applicant must be a pharmaceutical undertaking within the meaning of Section 4(18) AMG for the offered medicinal products and must remain so for the full contract term.
  • The company must have its registered seat in Germany, another EU Member State, or another EEA State, as stated in the notice.
  • Local representatives may participate only if they themselves qualify as pharmaceutical undertakings for the offered products.

Buyer

Location

Dortmund, DEU

Website

www.aok.de

Identifier

DE124159739

Activity

Health

Lots (3)

LOT-0001

North Rhine-Westphalia region

Regional open-house rebate agreement for North Rhine-Westphalia. Scope: non-exclusive rebate contracts for oncology parenteral preparations made from finished medicinal products, for the active substances bevacizumab, eribulin, rituximab and trastuzumab. The lot is described as an open-house model rather than a competitive procurement. Place of performance is Germany; no lot-specific city is stated.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Jul 2025 - Jul 2027

Category

Pharmaceutical products

Deadline

Deadline May 14, 2027

LOT-0002

Hamburg region

Regional open-house rebate agreement for Hamburg. Scope: non-exclusive rebate contracts for oncology parenteral preparations made from finished medicinal products, for the active substances bevacizumab, eribulin, rituximab and trastuzumab. The lot is described as an open-house model rather than a competitive procurement. Place of performance is Germany; no lot-specific city is stated.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Jul 2025 - Jul 2027

Category

Pharmaceutical products

Deadline

Deadline May 14, 2027

LOT-0003

Schleswig-Holstein region

Regional open-house rebate agreement for Schleswig-Holstein. Scope: non-exclusive rebate contracts for oncology parenteral preparations made from finished medicinal products, for the active substances bevacizumab, eribulin, rituximab and trastuzumab. The lot is described as an open-house model rather than a competitive procurement. Place of performance is Germany; no lot-specific city is stated.

SuppliesEU fundedElectronic submission

Location

Germany

Duration

Jul 2025 - Jul 2027

Category

Pharmaceutical products

Deadline

Deadline May 14, 2027

Procurement Details

Publication date
25 May 2025
Languages
German

Reference metadata

Legal basis
32014L0024

Reference IDs

Tender ID
338688-2025

Documents (1)

Similar tenders